NCT07440927 Stress Urinary Incontinence for Female Patients (CGM MUIT-2301)
| NCT ID | NCT07440927 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ceragem Clinical Inc. |
| Condition | Stress Urinary Incontinence (SUI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2024-12-13 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 96 participants in total. It began in 2024-12-13 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multicenter, prospective, randomized, double-blind, sham-controlled clinical trial conducted in female patients with stress urinary incontinence.
Eligibility Criteria
Inclusion Criteria: * Patients with urine leakage of ≥1 g on the standardized pad test Exclusion Criteria: * Patients with mixed urinary incontinence with predominant urgency urinary incontinence * Patients with stress urinary incontinence * Patients with overflow urinary incontinence
Contact & Investigator
Kyu Sung Lee, MD
PRINCIPAL INVESTIGATOR
Samsung Seoul Hospital
Frequently Asked Questions
Who can join the NCT07440927 clinical trial?
This trial is open to female participants only, aged 19 Years or older, studying Stress Urinary Incontinence (SUI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07440927 currently recruiting?
Yes, NCT07440927 is actively recruiting participants. Contact the research team at mbshin94@ceragem.com for enrollment information.
Where is the NCT07440927 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07440927 clinical trial?
NCT07440927 is sponsored by Ceragem Clinical Inc.. The principal investigator is Kyu Sung Lee, MD at Samsung Seoul Hospital. The trial plans to enroll 96 participants.